1. Market Research
  2. > Healthcare Market Trends
  3. > Medical Affairs Reputations (EU5): Multiple Sclerosis

Medical Affairs Reputations (EU5): Multiple Sclerosis

  • July 2015
  • -
  • Firstword Pharma

Summary

Table of Contents




Compare how well pharma Medical Affairs teams perform and find out which ones physicians rate, in our exclusive report on the Multiple Sclerosis sector. See how well your team stacks up against the competition and where work is still needed.

As well as this timely report weighing up the performance of the European Medical Affairs teams, you can also get an equivalent report for the US. If you buy both reports, we'll save you time and effort by giving you an additional free report that clearly sets out the differences in findings between both regions.

We asked neurologists who see patients with Multiple Sclerosis for their opinions on the Medical Affairs professionals they had dealt with in relation to at least one of the 9 MS drugs considered. Their frank responses reveal key areas of concern for you and what you should focus on to improve neurologists’ satisfaction. Areas where the teams are giving a solid performance are also highlighted.







Get Answers to Key Questions


What are the critical issues that physicians want help with from European Medical Affairs (MA) teams on?
How satisfied are physicians with the overall performance of MA teams? And how can performance be improved?
Which aspects of the services MA teams are providing are failing to satisfy physicians’ needs?
What are the preferred ways in which physicians want to interact with MA experts?
Which MA teams do physicians rate the best or worst for the products surveyed?



Products Included in Report

Bayer
Betaseron (Interferon-beta-1b)
Biogen
Avonex (Interferon-beta-1a)
Tecfidera (Dimethyl Fumarate)
Tysabri (Natalizumab)
Merck Serono
Rebif (Interferon-beta-1a)/BulletPoint>
Novartis
Extavia (Interferon-beta-1b)
Gilenya (Fingolimod)
Sanofi
Aubagio (Teriflunomide)
Teva
Copaxone (Glatiramer acetate)




Key Issues Explored

How physicians use the services of Medical Affairs teams
The importance of responding promptly to medical inquiries
The need-gap analysis of Medical Affairs roles – collectively and by product
The importance to physicians of regular, accurate, unbiased scientific and product information
Which Medical Affairs teams are performing best and worst for the Multiple Sclerosis sector

Methodology
Sample Distribution
148 neurologists from the UK, Germany, France, Spain and Italy


Interviewing Methodology
Data was collected via a 15-minute internet-based questionnaire that were carefully analysed.


Screening Criteria
Respondents screened to ensure that they:

See at least 10 patients for Multiple Sclerosis in a typical month
Have been in active practice for between 3 and 35 years
Devote at least 50% of time to direct patient care
Have had an interaction with a Medical Affairs professional in the past 6 months for at least one of the listed products





About FirstWord Reports

FirstWord is an innovative industry intelligence leader serving over 240,000 Pharma and MedTech professionals worldwide. FirstWord offers a range of products and services designed to help your company gain a competitive edge by making key business decisions with speed and confidence



FirstWord Pharma PLUS is a personalised and comprehensive intelligence service delivering up-to-the-minute pharma news, insight, analysis and expert views of importance to your company’s success.
FirstWord Reports deliver timely, need-to-know intelligence about your products, your competitors and your markets. Covering biosimilars, market access, medical affairs, sales & marketing, technology and therapy areas, FirstWord Reports provide expert views and intelligence on the challenges facing pharma today.


Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
Get This Report
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Psoriatic Arthritis - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Psoriatic Arthritis - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • December 2016
  • by GlobalData

PharmaPoint: Psoriatic Arthritis - Global Drug Forecast and Market Analysis to 2025 Summary Psoriatic arthritis (PsA) is a chronic immune-mediated arthritis typically affecting the large joints, especially ...

PharmaPoint: Hepatitis C Virus (HCV) Therapeutics - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Hepatitis C Virus (HCV) Therapeutics - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • December 2016
  • by GlobalData

PharmaPoint: Hepatitis C Virus (HCV) Therapeutics - Global Drug Forecast and Market Analysis to 2025 Summary Hepatitis C virus (HCV) is a small, enveloped RNA virus that causes acute and chronic infections ...

OpportunityAnalyzer: Diabetic Foot Ulcers - Opportunity Analysis and Forecast to 2025

OpportunityAnalyzer: Diabetic Foot Ulcers - Opportunity Analysis and Forecast to 2025

  • $ 10995
  • Industry report
  • December 2016
  • by GlobalData

OpportunityAnalyzer: Diabetic Foot Ulcers - Opportunity Analysis and Forecast to 2025 Summary Diabetic Foot Ulcer (DFU) and Diabetic Foot Infection (DFI) market is set to triple in value from $292.1 Million ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.